RT info:eu-repo/semantics/article
T1 Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE
A1 Aldred, Jason
A1 Anca-Herschkovitsch, Marieta
A1 Antonini, Angelo
A1 Bajenaru, Ovidiu
A1 Bourgeois, Paul
A1 Cubo Delgado, Esther
A1 Davis, Thomas L.
A1 Iansek, Robert
A1 Kovács, Norbert
A1 Kukreja, Pavnit
A1 Onuk, Koray
A1 Pontieri, Francesco E.
A1 Robieson, Weining
A1 Siddiqui, Mustafa S.
A1 Simu, Mihaela
A1 Standaert, David G.
A1 Chaudhuri, K. Ray
K1 5-2-1
K1 Criteria for advanced PD
K1 Dyskinesia
K1 LCIG
K1 Levodopa
K1 Levodopa-carbidopa intestinal gel
K1 Off time
K1 Parkinson’s disease
K1 Sistema nervioso-Enfermedades
K1 Nervous system-Diseases
K1 Medicina
K1 Medicine
K1 Neurología
K1 Neurology
AB Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.
PB Future Medicine
SN 1758-2024
YR 2020
FD 2020-09
LK http://hdl.handle.net/10259/8797
UL http://hdl.handle.net/10259/8797
LA eng
DS Repositorio Institucional de la Universidad de Burgos
RD 09-may-2024